The emerging psychedelics industry is expanding rapidly across the globe. With research demonstrating promising therapeutic potential for substances like psilocybin and MDMA to treat mental health conditions, this sector has attracted growing attention and investment.
Executive Spotlight: Dr Joseph Tucker, President & CEO of MagicMed Industries Inc greenmarketreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from greenmarketreport.com Daily Mail and Mail on Sunday newspapers.
Published: May 24, 2021
With this acquisition, Enveric will expand and complement its pipeline of naturally occurring cannabinoid compounds with a robust portfolio of psychedelic-derived molecules
Enveric aims to move into the clinic with novel cannabinoid and psychedelic-derived therapies to improve standard of care and serve unmet needs across multiple indications including oncology and CNS, such as PTSD
Upon closing, Dr. Joseph Tucker will be appointed Enveric Biosciences CEO and David Johnson as Executive Chairman
Management will host a conference call to discuss the transaction on Monday, May 24th at 8:30 a.m. ET
NAPLES, Fla., May 24, 2021 /PRNewswire/
Enveric Biosciences (NASDAQ: ENVB) ( Enveric or the Company ), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced that it has entered into a definitive agreement to acquire
Enveric Biosciences Inc (ENVB) Reports Acquisition of MagicMed Industries streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.